Potential Role of Exercise Induced Extracellular Vesicles in Prostate Cancer Suppression.
cancer physiology
exercise oncology
exercise physiology
extracellular vesicles
prostate cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
07
2021
accepted:
27
08
2021
entrez:
1
10
2021
pubmed:
2
10
2021
medline:
2
10
2021
Statut:
epublish
Résumé
Physical exercise is increasingly recognized as a valuable treatment strategy in managing prostate cancer, not only enhancing supportive care but potentially influencing disease outcomes. However, there are limited studies investigating mechanisms of the tumor-suppressive effect of exercise. Recently, extracellular vesicles (EVs) have been recognized as a therapeutic target for cancer as tumor-derived EVs have the potential to promote metastatic capacity by transferring oncogenic proteins, integrins, and microRNAs to other cells and EVs are also involved in developing drug resistance. Skeletal muscle has been identified as an endocrine organ, releasing EVs into the circulation, and levels of EV-containing factors have been shown to increase in response to exercise. Moreover, preclinical studies have demonstrated the tumor-suppressive effect of protein and microRNA contents in skeletal muscle-derived EVs in various cancers, including prostate cancer. Here we review current knowledge of the tumor-derived EVs in prostate cancer progression and metastasis, the role of exercise in skeletal muscle-derived EVs circulating levels and the alteration of their contents, and the potential tumor-suppressive effect of skeletal muscle-derived EV contents in prostate cancer. In addition, we review the proposed mechanism of exercise in the uptake of skeletal muscle-derived EVs in prostate cancer.
Identifiants
pubmed: 34595123
doi: 10.3389/fonc.2021.746040
pmc: PMC8476889
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
746040Informations de copyright
Copyright © 2021 Zhang, Kim, Wang, Newton, Galvão, Gardiner, Hill and Taaffe.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1281-8
pubmed: 27389872
Cell Metab. 2018 Jan 9;27(1):237-251.e4
pubmed: 29320704
Stem Cells Dev. 2014 Jul 1;23(13):1429-36
pubmed: 24564699
Nat Rev Endocrinol. 2012 Apr 03;8(8):457-65
pubmed: 22473333
Nat Rev Urol. 2020 Jan;17(1):11-27
pubmed: 31827264
Neoplasia. 2009 Oct;11(10):1042-53
pubmed: 19794963
Nat Rev Urol. 2021 Sep;18(9):519-542
pubmed: 34158658
J Physiol. 2011 Aug 15;589(Pt 16):3983-94
pubmed: 21690193
Eur Urol. 2015 Jan;67(1):33-41
pubmed: 25129854
Nat Rev Urol. 2016 May;13(5):258-65
pubmed: 26954333
Oncotarget. 2016 Aug 9;7(32):51991-52002
pubmed: 27437771
Commun Biol. 2021 Jan 26;4(1):119
pubmed: 33500545
J Extracell Vesicles. 2015 Jul 02;4:28239
pubmed: 26142461
Oncol Rep. 2016 Mar;35(3):1237-44
pubmed: 26707854
BMC Obes. 2014 Aug 22;1:13
pubmed: 26937283
Basic Res Cardiol. 2017 Jul;112(4):38
pubmed: 28534118
Exerc Immunol Rev. 2020;26:80-99
pubmed: 32139350
PLoS One. 2015 May 08;10(5):e0125094
pubmed: 25955720
PLoS One. 2012;7(12):e50999
pubmed: 23251413
Cells. 2018 Aug 01;7(8):
pubmed: 30071693
Cell. 2018 Dec 13;175(7):1756-1768.e17
pubmed: 30550785
Int J Obes (Lond). 2020 May;44(5):1108-1118
pubmed: 31578459
Int J Endocrinol. 2013;2013:746281
pubmed: 24298283
Mol Cancer. 2013 Oct 08;12(1):118
pubmed: 24103426
Crit Rev Oncog. 2015;20(5-6):407-17
pubmed: 27279238
Clin Transl Med. 2021 Apr;11(4):e381
pubmed: 33931969
Front Cell Dev Biol. 2021 Feb 05;9:634853
pubmed: 33614663
Semin Cell Dev Biol. 2017 Jul;67:48-55
pubmed: 28104520
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Br J Cancer. 2013 May 28;108(10):1925-30
pubmed: 23632485
J Extracell Vesicles. 2014 Jun 25;3:
pubmed: 25018864
J Clin Oncol. 2011 Feb 20;29(6):726-32
pubmed: 21205749
J Biol Chem. 2015 Feb 20;290(8):4545-4551
pubmed: 25568317
CA Cancer J Clin. 2019 Nov;69(6):468-484
pubmed: 31617590
Oncogene. 2019 Mar;38(10):1751-1763
pubmed: 30353168
Oncogene. 2009 Oct 1;28(39):3487-98
pubmed: 19597474
Maturitas. 2009 Aug 20;63(4):323-8
pubmed: 19615834
Metabolism. 2012 Dec;61(12):1725-38
pubmed: 23018146
Front Biosci. 2007 May 01;12:4254-66
pubmed: 17485372
PLoS One. 2013 Jul 05;8(7):e67579
pubmed: 23861774
Nat Rev Cancer. 2002 Feb;2(2):91-100
pubmed: 12635172
Prostate. 2007 May 15;67(7):764-73
pubmed: 17373716
Front Physiol. 2018 May 24;9:532
pubmed: 29881354
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
J Theor Biol. 2014 Sep 21;357:143-9
pubmed: 24859414
J Natl Cancer Inst. 2014 Apr;106(4):dju036
pubmed: 24627275
Nat Cell Biol. 2019 Jan;21(1):9-17
pubmed: 30602770
Front Oncol. 2020 Apr 17;10:558
pubmed: 32363164
Mol Cell Biochem. 2018 Mar;440(1-2):115-125
pubmed: 28819811
Front Endocrinol (Lausanne). 2019 Aug 02;10:524
pubmed: 31428053
Cell Physiol Biochem. 2016;39(6):2381-2397
pubmed: 27832652
J Clin Oncol. 2010 Jan 10;28(2):340-7
pubmed: 19949016
J Clin Endocrinol Metab. 2019 Oct 1;104(10):4804-4814
pubmed: 30933285
Cancer Sci. 2016 Apr;107(4):385-90
pubmed: 26797692
Endocrinology. 2021 Sep 1;162(9):
pubmed: 34232289
Cell Mol Life Sci. 2011 Aug;68(16):2667-88
pubmed: 21560073
J Clin Endocrinol Metab. 2002 Feb;87(2):599-603
pubmed: 11836291
Br J Cancer. 2012 Feb 14;106(4):768-74
pubmed: 22240788
Front Physiol. 2019 May 07;10:522
pubmed: 31133872
Cancer Res. 2011 Jun 1;71(11):3889-95
pubmed: 21610110
Mol Cancer Res. 2016 Nov;14(11):1136-1146
pubmed: 27439335
Eur Urol. 2012 Apr;61(4):664-75
pubmed: 22169079
Philos Trans R Soc Lond B Biol Sci. 2014 Sep 26;369(1652):
pubmed: 25135966
Med Sci Sports Exerc. 2021 Mar 1;53(3):459-469
pubmed: 32890199